Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

The Lancet

Topics

Medicine

Cancer Oncology

Internal Medicine

Surgery

Hepatology

Show all topics

DOI

10.1016/s0140-6736(23)00961-3